Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...
In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
Launching in 2008 as a drug literature review blog by Rob Dickins, Psychedelic Press has brought readers a host of unique insights into psychedelic thought and...
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
Awakn Life Sciences has completed the sale of Awakn London Limited Ltd.,
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
Timmy Davis of the Conservative Drug Policy Reform Group (CDPRG) tells Psychedelic Health about the organisation’s campaign to reschedule psilocybin in a bid to increase psychedelic...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
A UK Parliamentary debate on 18 May saw crossparty calls to conduct an urgent review of the evidence for psilocybin’s current status as a Schedule 1...
The Royal College of Psychiatrists, Heroic Hearts and other leading mental health charities have written letters to the Veterans Minister and the Minister of State for...
